Wallachbeth Capital Announces Pricing of Bullfrog AI’s Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
Description:
JERSEY CITY, N.J., Oct. 18, 2024 /PRNewswire/ — WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“Bullfrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, has entered into a definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,000 shares of common stock (together with the registered direct offering) at a combined purchase price of $2.00.
Impact on Me:
As an individual investor, the news of Bullfrog AI’s Registered Direct Offering and Concurrent Private Placement with an aggregate gross proceeds of $3.13 million may signal a potential opportunity for investment. With the company focusing on technology-enabled drug development using AI and machine learning, there is a chance for significant growth and returns on investment. It would be essential to conduct further research and analysis before deciding whether to participate in this offering.
Impact on the World:
The announcement of Bullfrog AI’s fundraising activities can have broader implications for the pharmaceutical and biotech industries. By leveraging AI and machine learning in drug development, Bullfrog AI is demonstrating the potential for innovation and advancement in the field. This could lead to the development of new and improved pharmaceuticals and biologics, ultimately benefiting patients worldwide with more effective treatments and therapies.
Conclusion:
In conclusion, Wallachbeth Capital’s pricing of Bullfrog AI’s Registered Direct Offering and Concurrent Private Placement signifies a significant milestone for both companies. The infusion of funds will enable Bullfrog AI to further its research and development efforts, potentially leading to groundbreaking advancements in the pharmaceutical industry. As investors, it is essential to stay informed about such developments and consider the potential opportunities they present.
